|
Diabetes Therapy to Improve BMI and Lung Function in CF Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Diabetes Therapy to Improve BMI and Lung Function in CF conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Diabetes Therapy to Improve BMI and Lung Function in CF Clinical research trials and Diabetes Therapy to Improve BMI and Lung Function in CF health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Diabetes Therapy to Improve BMI and Lung Function in CF. Diabetes Therapy to Improve BMI and Lung Function in CF Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Diabetes Therapy to Improve BMI and Lung Function in CF clinical trial. Test subjects typically receive the most expert healthcare available for their Diabetes Therapy to Improve BMI and Lung Function in CF condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Diabetes Therapy to Improve BMI and Lung Function in CF  Diabetes Therapy to Improve BMI and Lung Function in CF
Diabetes Therapy to Improve BMI and Lung Function in CF
For Condition: Cystic Fibrosis,Diabetes Mellitus
Status: Recruiting
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) , Cystic Fibrosis Foundation,Novo Nordisk Pharmaceuticals
Synopsis: To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize pulmonary function in cystic fibrosis (CF).
Details: The primary objective of this research is to determine whether treatment with either insulin or an oral diabetes agent that increases endogenous insulin secretion will improve BMI and pulmonary function in cystic fibrosis patients who have diabetes without fasting hyperglycemia.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 16 Years/
Genders: Both
Protocol Entry Criteria: - Diabetic glucose pattern by oral glucose tolerance test (OGTT) of >200 at 120 min. (stable and healthy at time of OGTT) - Fasting glucose levels <126. - Weight stable within 5% in previous 3 months. - Free from illness for two months. - Male and female 16 and older, who are done growing - Willing to come in for visits every 3 months. - Patients receiving infrequent short bursts of systemic glucocorticoids may be considered for the study inclusion if: a. they have not received systemic glucocorticoids steroids for at least one month, b. they did not receive the steroids for more than 14 consecutive days or 28 days total in six months
Total Enrollment: 150
Location and Contact Information:
Stanford University *Recruiting*
Palo Alto, California, 94304
United States
Recruiting Noreen Henig 650-723-6381
Vanderbilt University Medical Center *Recruiting*
Nashville, Tennessee, 37232-2650
United States
Recruiting Bonnie Slovis 615-322-3412
Baystate Medical Center *Recruiting*
Springfield, Massachusetts, 01199
United States
Recruiting Holley Allen 413-794-4441
Children's Hospital of Pittsburgh *Recruiting*
Pittsburgh, Pennsylvania, 15213-2583
United States
Recruiting Joseph Pilewski 412-692-2164
University of Minnesota Medical Center *Recruiting*
Minneapolis, Minnesota, 55455
United States
Recruiting Trish Grover 612-624-0135
University of Utah *Recruiting*
Salt Lake City, Utah, 84132-4701
United States
Recruiting Theodore Liou 801-581-7806
St. Michael's Hospital *Recruiting*
Toronto, Ontario, M5B 1W8
Canada
Recruiting Elizabeth Tullis 416-864-5651
Additional Information:
Study ID Numbers: 58356DK;
Study Start Date: June 2001
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00072904
Other Diabetes Mellitus Studies:
1. Role of Genetic Factors in the Development of Lung Disease
2. Randomized Study of Pancrelipase With Bicarbonate (PANCRECARB) Capsules in Reducing Steatorrhea in Patients With Cystic Fibrosis
3. Bone Health of People with Cystic Fibrosis
4. Study of Mycobacterial Infections
5. Phase I Study of Liposome-Mediated Gene Transfer in Patients with Cystic Fibrosis
Related Studies:
Other Diabetes Mellitus Clinical Trials
Other Minnesota Clinical Trials
Other Minneapolis Clinical Trials
Diabetes Therapy to Improve BMI and Lung Function in CF
|
|
|
|
|
|
|
|
